Research Topics
Genomes and Genes | Joanna J PhillipsSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Novel therapeutic targets in the brain tumor microenvironmentJoanna J Phillips
Department of Neurological Surgery, University of California San Francisco, USA
Oncotarget 3:568-75. 2012..Here we examine HSPGs and the enzymes that modify them in GBM. We compare their expression across tumor subtypes, their potential roles in oncogenesis, and their potential as novel therapeutic targets in GBM...- Heparan sulfate sulfatase SULF2 regulates PDGFRα signaling and growth in human and mouse malignant gliomaJoanna J Phillips
Department of Neurological Surgery, UCSF, San Francisco, California 94158, USA
J Clin Invest 122:911-22. 2012..Our results suggest the bioavailability of growth factors from the microenvironment is a significant contributor to tumor growth in a major subset of human GBM... - Pituicytoma: characterization of a unique neoplasm by histology, immunohistochemistry, ultrastructure, and array-based comparative genomic hybridizationJoanna J Phillips
Neuropathology Unit, University of California San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143 0102, USA
Arch Pathol Lab Med 134:1063-9. 2010..This pattern of genetic changes only partially overlaps with the genomic alterations reported in pituitary adenomas. In summary, our data suggest that pituicytomas are a unique subset of tumors of the sellar region... 
Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomasAdam Elkhaled
Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA 94158, USA
Sci Transl Med 4:116ra5. 2012..Such information may augment the ability of clinicians to monitor therapeutic response and provide criteria for stratifying patients to specific treatment regimens...- Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomasJane R Engler
Department of Neurological Surgery, University of California San Francisco, San Francisco, California, United States of America
PLoS ONE 7:e43339. 2012..These studies support a role for the immune response, particularly the microglia/macrophage response, in the biology of an important subset of GBM. Identification of this subset may be important for future therapeutic stratification... - Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapyEmmanuelle Huillard
Department of Pediatrics, University of California, San Francisco, CA 94143, USA
Proc Natl Acad Sci U S A 109:8710-5. 2012..Our findings indicate a rational therapeutic strategy for treating a subset of pediatric astrocytomas with BRAF(V600E) mutation and CDKN2A deficiency... - Choline metabolism, proliferation, and angiogenesis in nonenhancing grades 2 and 3 astrocytomaTracy R McKnight
Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA
J Magn Reson Imaging 33:808-16. 2011..PC and glycerophosphocholine (GPC) are involved in phospholipid metabolism that accompanies mitosis. PC is the predominant peak in Grade 4 astrocytoma (GBM) while GPC dominates in AS2... - Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR ImagingRamon F Barajas
Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94158 2330, USA
Neuro Oncol 14:942-54. 2012..Image-guided tissue acquisition and assessment of residual tumor from treatment-naive GBM should be guided by DSC in CE regions and by DWI in NE regions... - Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatmentRintaro Hashizume
Department of Neurological Surgery, Brain Tumor Research Center, University of California San Francisco, San Francisco, CA 94143 0520, USA
J Neurooncol 110:305-13. 2012..The hTERT modified cells are tumorigenic in athymic rodents, and produce brainstem tumors that recapitulate the infiltrative growth of brainstem gliomas in patients... - VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complexKan V Lu
Department of Neurological Surgery, University of California, Helen Diller Family Cancer Research Center, San Francisco, CA 94143, USA
Cancer Cell 22:21-35. 2012..Inhibition of MET in GBM mouse models blocks mesenchymal transition and invasion provoked by VEGF ablation, resulting in substantial survival benefit... - Clinical stratification of glioblastoma based on alterations in retinoblastoma tumor suppressor protein (RB1) and association with the proneural subtypePatricia Goldhoff
Division of Neuropathology, Department of Pathology, University of California, San Francisco, San Francisco, California 94143, USA
J Neuropathol Exp Neurol 71:83-9. 2012..01). These data support the use of IHC for determining RB1 status in clinical GBM specimens and suggest that RB1 alterations may be more common in certain GBM subgroups... 
Neurolisteriosis presenting as cervical myelitis in an immunocompetent patientS Andrew Josephson
Department of Neurology, University of California, San Francisco, CA 94143-0114, USA
Neurology 66:1122-3. 2006- Proteoglycans and their roles in brain cancerAnna Wade
Department of Neurological Surgery, UCSF, San Francisco, CA, USA Brain Tumor Research Center, UCSF, San Francisco, CA, USA
FEBS J 280:2399-417. 2013.... - EMR-3: a potential mediator of invasive phenotypic variation in glioblastoma and novel therapeutic targetAri J Kane
Department of Neurological Surgery, Division of Neuropathology, University of California at San Francisco, San Francisco, California 94143, USA
Neuroreport 21:1018-22. 2010..EMR-3 is a potential mediator of cellular invasion in GBM. Given the poor survival associated with high levels of EMR-3 expression in glioma patients, our results provide impetus to explore EMR-3 as a potential therapeutic target... - Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imagingIlwoo Park
Surbeck Laboratory of Advanced Imaging, Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA
J Magn Reson Imaging 33:1284-90. 2011..To demonstrate the feasibility of using DNP hyperpolarized [1-(13)C]-pyruvate to measure early response to temozolomide (TMZ) therapy using an orthotopic human glioblastoma xenograft model... - Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYCFredrik J Swartling
University of California, Department of Neurology, Brain Tumor Research Center and Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94158, USA
Cancer Cell 21:601-13. 2012..These differences were regulated in part by the transcription factor SOX9, activated in the SHH subclass of human medulloblastoma. Our results demonstrate context-dependent transformation of NSCs in response to a common oncogenic signal... - Pyruvate kinase M2 expression, but not pyruvate kinase activity, is up-regulated in a grade-specific manner in human gliomaJoydeep Mukherjee
Department of Neurological Surgery, University of California San Francisco, San Francisco, California, United States of America
PLoS ONE 8:e57610. 2013..These results show that pyruvate kinase M expression, but not pyruvate kinase activity, is regulated in a grade-specific manner in glioma, but that changes in both PK activity and PKM2 expression contribute to growth of GBM... - Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBMRadhika Srinivasan
Department of Radiology and Biomedical Imaging, 1700 4th Street, Byers Hall, Suite 301, San Francisco, CA 94143 2532, USA
Neuro Oncol 12:1152-61. 2010..Low levels of MCI for tumor were associated with a reduced apparent diffusion coefficient and elevated choline-N-acetyl-aspartate index derived from in vivo MR images...